Neogenomics (NEO) EBITDA Margin (2010 - 2026)
Neogenomics' (NEO) quarterly EBITDA Margin came in at 4.85% in Q2 2026, up 2142.0% YoY from 0.22% in Q2 2025, and up 50.41% on a QoQ basis from 9.77% in Q1 2026.
Neogenomics (NEO) EBITDA Margin (2010 - 2026) Analysis & Trends
Neogenomics (NEO) has 17 years of EBITDA Margin data on file, last reported at 4.85% in Q2 2026.
- Quarterly EBITDA Margin rose 2142.0% year-over-year to 4.85% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 8.93% (up 776.0% YoY) and the FY2025 annual result came in at 15.93%, down 199.0% from the prior year.
- EBITDA Margin improved to 4.85% in Q2 2026, from 9.77% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 4.85% in Q2 2026 to a low of 44.4% in Q1 2022.
- A 5-year average of 18.6% and a median of 16.24% in 2025 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin plunged 3133 bps — and 2026, when it surged 2142 bps.
- Tracing NEO's EBITDA Margin over 5 years: stood at 19.02% in 2022, then jumped by 37 bps to 11.94% in 2023, then increased by 10 bps to 10.7% in 2024, then soared by 34 bps to 7.05% in 2025, then surged by 31 bps to 4.85% in 2026.
- The last three EBITDA Margin figures came in at 4.85% (Q2 2026), 9.77% (Q1 2026), and 7.05% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 17.40% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 17.99% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 34.98% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 21.74% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 11.58% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -13.42% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 21.14% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 31.97% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 15.08% |
| 10 | Neogenomics | 2.05 Bn | 1.90 Bn | 91.88 Mn | -4.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.85% |
| Mar 31, 2026 | -9.77% |
| Dec 31, 2025 | -7.05% |
| Sep 30, 2025 | -14.38% |
| Jun 30, 2025 | -26.27% |
| Mar 31, 2025 | -16.56% |
| Dec 31, 2024 | -10.70% |
| Sep 30, 2024 | -12.63% |
| Jun 30, 2024 | -13.34% |
| Mar 31, 2024 | -19.56% |
| Dec 31, 2023 | -11.94% |
| Sep 30, 2023 | -15.92% |
| Jun 30, 2023 | -20.35% |
| Mar 31, 2023 | -25.56% |
| Dec 31, 2022 | -19.02% |
| Sep 30, 2022 | -30.68% |
| Jun 30, 2022 | -31.74% |
| Mar 31, 2022 | -44.40% |
| Dec 31, 2021 | -33.06% |
| Sep 30, 2021 | -32.73% |